NCT05985850View on ClinicalTrials.gov

Evaluating Tetrahydrocannabinol as an Adjunct to Opioid Agonist Therapy

PHASE2RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 23, 2024

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2027

Conditions
Opioid Use DisorderMethadoneCannabisFentanyl
Interventions
DRUG

Aurora 1:1 Drops (Indica)

Aurora 1:1 Drops (Indica) is created by extracting cannabinoids and terpenes and the concentrated extract is then diluted in medium-chain triglyceride (MCT) oil for optimal use.

DRUG

Placebo

Medium-chain triglyceride (MCT) oil with the same appearance, color, and taste as the Aurora 1:1 Drops (Indica).

Trial Locations (1)

V6Z 1Y6

RECRUITING

Rapid Access Addiction Clinic (RAAC), St. Paul's Hospital, Vancouver

All Listed Sponsors
collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

lead

BC Centre on Substance Use

OTHER